Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: CON, TRI

BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test at the Point of Care

CHICAGO, Nov. 26, 2020 /PRNewswire/ -- BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting. 

Study will expand access to antibody testing outside of laboratory settings

Although Covid-19 deaths and new confirmed cases continue to rise across nursing homes in the US, many of those infected do recover. This has led to growing interest in the relationship between antibodies and their protective value whether generated by previous Covid-19 exposure or by a vaccine, once available. 

At present, most antibody tests on the market require samples to be sent to a lab for analysis. The extra cost and time associated has constrained population wide studies of SARS-CoV-2 antibodies. 

"An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff," says Dr. Michael Fang, BASE10 CEO.  

"This research is an important milestone in our efforts to expand access to antibody testing," says Elizabeth Freund, VP of Innovation at BASE10. "DNA Link's AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab. Many factors have the potential to affect test performance in lesser controlled settings so it's an ambitious goal to be sure. However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we'll be one step closer to FDA emergency use authorization for point of care use."

The study is set to launch in December. 

About BASE10 Genetics, Inc.
BASE10 is a precision medicine company based in Chicago. BASE10's proprietary platform identifies precision diagnostics technologies with high potential for improving health outcomes, and creates turnkey, disease management programs that can be deployed at scale for insurance payors.

For more information about BASE10 Genetics and its solutions, contact media@base10genetics.com.

About DNA Link, Inc.
DNA Link, Inc. is a leading genomic service corporation based in Korea with a focus on personalized medicine and new drug development. The company combines biotechnology with information & communications technology to support total analysis of genomic and clinical information to accelerate research and development in the field of bio-industry and genomic analysis industry. 

For more information about DNA Link and its solutions, contact ikjun.choi@dnalink.com


SOURCE BASE10 Genetics, Inc.

These press releases may also interest you

at 09:25
Virios Therapeutics, Inc. , a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that Greg Duncan, Chairman and Chief Executive Officer,...

at 09:25
Axuall, Inc. announced today that it is launching a pilot with MedStar Health through its MedStar Institute for Innovation (MI2) to further deploy and develop new technologies that more efficiently verify the credentials of newly-recruited clinical...

at 09:20
Worldwide Clinical Trials, Inc., (Worldwide) the industry's leading global, mid-sized, full-service contract research organization (CRO), today announced the appointment of Peter Lammers as Executive Vice President, Global Marketing and Commercial...

at 09:18
Nearly 12,000 VITAS Healthcare professionals will benefit from a significant amount of supplies, including reusable face coverings and hand sanitizer, from AT&T. AT&T is a healthcare technology collaborator with VITAS....

at 09:15
Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, today announced the appointment of Gwendolyn Bingham, Karen Golz and Diana Nole to its board of directors. These highly...

at 09:15
ImmunityBio, Inc., a privately held immunotherapy company, today announced the presentation of encouraging data in non-small cell lung cancer (NSCLC) from the company's ongoing Phase 2b study, QUILT-3.055 (ClinicalTrials.gov: NCT03228667) at the...

News published on 26 november 2020 at 20:41 and distributed by: